Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies

Adam Rosenthal, Ph.D., Founder and chief executive officer of Star Therapeutics

“Our mission is to develop best-in-disease therapies at scale for the millions of patients with diseases of significant unmet need”

Adam Rosenthal, Ph.D., Founder and chief executive officer of Star Therapeutics

“This financing marks the next phase for Star, building on our team’s track record of discovering and developing novel medicines. With an experienced team, a growing pipeline and the support of a top-tier investor base, we are well positioned to advance our current programs into the clinic and continue to add new, highly innovative programs to our pipeline in order to meaningfully improve patient outcomes.”

Carl L. Gordon, Ph.D., CFA, Managing partner at OrbiMed

“I have worked with this team across three different companies, and have seen firsthand their ability to identify important therapeutic opportunities and translate them into medicines with the potential to make an impact for patients”

Carl L. Gordon, Ph.D., CFA, Managing partner at OrbiMed

“We believe Star has the team, scientific approach and pipeline to build on those achievements in its next phase of growth.”

Vish Sridharan, M.D., Assistant portfolio manager and research analyst at Janus Henderson Investors

“Star stood out to us because of the strength of its team and its proven ability to invent and develop innovative therapies”

Vish Sridharan, M.D., Assistant portfolio manager and research analyst at Janus Henderson Investors

“We do not often invest in companies at this stage of development, which reflects our conviction in Star’s ability to repeatedly identify areas of significant unmet need and develop differentiated therapies to address them. We look forward to supporting the team as it advances its growing pipeline into the clinic and continues to develop the next generation of therapies for patients.”